GTBP 10-Q filed 2026-11-16 | Key takeaways
GTBP filed its 10-Q; the most relevant disclosure change is added Reverse Stock Split: On September 8, 2026, the company effectuated a reverse stock-split of its Common Stock at a ratio of 1-for-25. The reverse stock split reduced the number of shares outstanding from 45,109,497 pre-split shares to 1,804,379 post-split shares. The total authoriz.
Key takeaways
Reverse stock split: The company completed a 1-for-25 reverse stock split on September 8, 2026, reducing outstanding shares from 45.1 million pre-split to 1.8 million post-split.
Series M Preferred Stock: The company raised $7.6 million in net proceeds through a September 2026 private placement of Series M Preferred Stock and warrants, with up to $31.2 million in additional greenshoe rights available.
Preferred stock cleanup: All outstanding shares of Series C Preferred Stock were converted and eliminated via Certificates of Elimination filed September 2, 2026, along with 10 other preferred stock series.
Nasdaq compliance: The company regained compliance with the $1.00 minimum bid price requirement in September 2022, 2026 after receiving two 180-day extension letters.
Litigation settlement: The Silberfein, DiPietro, and Werthman Trust matters were settled in October 2026 through issuance of approximately 46,000 shares of Common Stock valued at $300,000.
Clinical progress: GTB-5550 IND was cleared by FDA in January 2026 with first patient dosed in May 2026; GTB-3650 clinical trial ongoing with first 4 cohorts enrolled.
Going concern: The company's independent registered public accounting firm raised substantial doubt about ability to continue as a going concern, and the company may need additional financing to fund operations.
Key metrics
Disclosure changes
- Reverse Stock Split
On September 8, 2026, the company effectuated a reverse stock-split of its Common Stock at a ratio of 1-for-25. The reverse stock split reduced the number of shares outstanding from 45,109,497 pre-split shares to 1,804,379 post-split shares. The total authorized shares were reduced from 265,000,000 to 26,500,000 shares.
The reverse stock split increases the per-share price of the company's common stock while proportionately reducing the number of shares outstanding, affecting shareholder equity and per-share metrics. - Series M Preferred Stock Issuance
On September 14, 2026, the company entered into a securities purchase agreement providing for the issuance of 8,611.11 shares of Series M Preferred Stock with aggregate stated value of $8,611,111, warrants to purchase 1,411,651 shares of Common Stock at $6.10 per share, and vesting warrants for 5,684,522 shares. Net proceeds were $7,640,000 with up to $31.2 million in additional greenshoe rights available.
The company raised $7.6 million in new capital through a preferred stock and warrant financing, with significant additional potential capital through greenshoe rights. - Series C Preferred Stock Elimination
As of September 30, 2026, there were no shares of Series C Preferred Stock issued and outstanding. All 96,230 outstanding shares were converted and eliminated via Certificate of Elimination filed September 2, 2026.
The elimination of Series C Preferred Stock simplifies the company's capital structure. - Multiple Preferred Stock Series Eliminated
On September 2, 2026, the company filed Certificates of Elimination to eliminate from the Charter all matters related to 11 series of preferred stock: Series A through K (excluding Series L and M).
The company cleaned up its charter by eliminating references to preferred stock series that are no longer designated, issued, or outstanding. - Nasdaq Minimum Bid Price Compliance
On September 22, 2026, the company received notice from Nasdaq that it had regained compliance with the Minimum Bid Price Requirement. The company's Common Stock maintained a closing bid price above $1.00 per share for at least ten consecutive business days.
Regaining Nasdaq compliance avoids potential delisting and maintains the company's ability to access public capital markets. - Legal Proceedings Settlement
In October 2026, the company settled all claims in the Silberfein, DiPietro, and Werthman Trust litigation by issuing approximately 46,000 shares of Common Stock with a fair value of approximately $300,000. Each plaintiff filed a notice of discontinuance with prejudice on October 23, 2026.
The settlement resolves pending litigation related to alleged failures to deliver conversion shares, eliminating uncertainty around potential damages.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow GTBP in real time
Get material earnings, filing, IR, and earnings-call alerts by email.